

Confinement Predictions for ITER

We take issue with the way James Glanz's article of 6 December about plasma turbulence and ITER (International Thermonuclear Experimental Reactor) performance (News & Comment, p. 1600) represents the significance of the predictions of a particular turbulent transport model relative to confinement projections for ITER.

Projections of ITER confinement performance are based at present primarily on extrapolations of a large body of experimental data. This methodology for confinement projection has been reviewed and endorsed by an international working group of experts on the subject and by the ITER Technical Advisory Committee—an international group of senior plasma physicists and fusion engineers. We agree with the conclusions of both of these groups that extrapolating experimental data provides at present the most reliable basis for projecting ITER confinement.

Present theoretical transport models are not yet complete, nor are they sufficiently validated for predicting ITER performance. Nonetheless, theoretical confinement projections for ITER, based on several different transport models, bracket the projections obtained from the experimental data, thus increasing confidence in

the latter. The ITER team and associated expert groups are developing and validating improved projection methods, including both experimental extrapolation and theoretical models, and these efforts should lead to improved confidence in confinement projections.

Such recent theoretical advances as the work highlighted in Glanz's article, combined with recent experimental advances in tokamak operation, including those in which turbulent transport is suppressed, represent exciting progress in understanding the fundamental physics of tokamaks.

Weston M. Stacey*

*Fusion Research Center,
Georgia Institute of Technology,
Atlanta, GA 30332-0225, USA
E-mail: weston.stacey@me.gatech.edu*


*On behalf of the members of the ITER Steering Committee—U.S., the independent U.S. technical advisory committee on ITER composed of the following senior representatives from a broad range of institutions within the U.S. fusion program: W. M. Stacey, chair (Georgia Institute of Technology); R. D. Hazeltine (University of Texas); M. Porkolab (Massachusetts Institute of Technology); D. M. Meade (Princeton Plasma Physics Laboratory); M. J. Saltmarsh (Oak Ridge National Laboratory); R. E. Siemon (Los Alamos National Laboratory); T. Simeonen (General Atomics); D. L. Smith (Argonne National Laboratory); D. Steiner (Rensselaer Polytechnic Institute); K. I. Thomasen (Lawrence Livermore National Laboratory); and M. A. Ulrickson (Sandia Laboratories).

The grand vision of the ITER experiment may be colliding with technical, as well as physical, reality. Less discussed outside the fusion community are, for example, the still unresolved structural integrity problems of the components facing or close to the plasma. Electromagnetic and thermal loadings associated with abnormal plasma behavior (for example, disruptions and runaway electrons) may damage components so severely that a definitive reactor shutdown is required after the first event. Even under normal operational conditions, the structural viability of all the high-heat flux components has not been demonstrated.

The current ITER project is the last part of the approximately 18-year-old effort to develop a tokamak "next-step" device. This effort has excelled in terms of unprecedented international cooperation and also in terms of its unprecedented, unfavorable cost-to-progress ratio. Almost \$1.5 billion has been globally swallowed since the inception of the International Tokamak Reactor project in 1978 (with the United States, Europe, Japan, and the former Soviet Union collaborating), but attempts to solve the integrity problems and numerous other problems in most of the engineering and technology areas have

To **save an hour**
each time you
purify histidine-
tagged proteins,
put it on the
tip of a syringe

Circle No. 39 on Readers' Service Card



resulted in cyclic design iterations that have scarcely gone beyond the conceptual, or preliminary, stage.

Ezio Zolti
Watzmannring 73,
D-85748 Garching, Germany
E-mail: zolti@t-online.de

diseases, including Parkinson's, Huntington's, and multiple sclerosis.

Pratibha Chaturvedi
Department of Microbiology and
Immunology,
University of Western Ontario,
London, Ontario, N6A 5C1 Canada
E-mail: pchaturv@julian.uwo.ca

Rinee Mukherjee
John P. Robarts Research Institute,
100 Perth Drive,
London, Ontario, N6A 5K8 Canada
E-mail: rmukherj@julian.uwo.ca

Fred Lenherr
Applied Computing Systems Institute of
Massachusetts,
Computer Science Department,
University of Massachusetts,
Amherst, MA 01003, USA
E-mail: lenherr@tiac.net

Surfing the Neuroscience Net

"Surfing the Net" can be confusing if one does not know what to look for or where to look. The recent article by Floyd E. Bloom (15 Nov., p. 1104) will be helpful to neuroscientists and provides information for anyone with specific or general questions about neuroscience.

For researchers interested in neurodegenerative diseases, the catalog of sites at <http://www.sciweb.com/directories.html> can be useful. This site provides a list of World Wide Web sites on many subjects, including a disease-associated site at http://www.sciweb.com/dir_disease.html. This site has listings of other sites on various diseases, including Alzheimer's, at <http://med-amsa.bu.edu/Alzheimer/home.html>. One site at <http://med-amsa.bu.edu/Alzheimer/neurodis.htm> has listings for other neurodegenerative

Bloom's superb article omitted one Web site that allows full-text searching on a database of more than 110,000 Web pages, all of which have been prequalified as relevant to neuroscience. The site allows easy access to an estimated 5000 megabytes of actual Web page content, including text, images, and movies. English and several foreign languages can be used, or a special query syntax can be employed by those wishing to master it.

The URL for this site is <http://www.acsiom.org/nsr/neuro.html>. The service is free, noncommercial, and open to all. The only request is that users limit the total number of URLs requested for any single query to 200. There is no limit on the total number of different queries one may submit.

The Perspective "The imaging of individual atoms" by David A. Jefferson (18 Oct., p. 369) does an excellent job of helping the reader appreciate the work of P. D. Nellist and S. J. Pennycook (Reports, 18 Oct., p. 413) in advancing atomic resolution microscopy. Jefferson correctly points out that, while x-rays and neutrons have contributed to atomic resolution structure studies of crystals, they have not done so when it comes to single individual atoms. But his statement that "no lens is available for either x-rays or neutrons" misses an active and growing area of research. On the basis of pioneering work by A. V. Baez (1), diffractive lenses (zone plates and Bragg-Fresnel structures) have been fabricated to focus both x-rays (2) and neutrons (3). The

A column from
the HisTrap™ Kit,
magnified 280%.

Would you like to save one hour in histidine-tagged protein purification?
To load, purify and elute in 15 minutes? Now it's possible—time after time.

HisTrap kit: saving an hour couldn't be simpler

The HisTrap™ Kit presents you with a solution so simple it works with a syringe. Inside the kit is all you'll need for up to ten affinity purification runs: pre-packed cartridges, ready-made stock solutions, a protocol that's easy to follow, and, of course, a syringe.

You'll get high purity recombinant proteins as the kit lets you use the well-known binding of poly(histidine) sequences to immobilized nickel. What's more, it saves you the effort of weighing out buffer salts.

Molecular biologists have been purifying recombinant proteins with Pharmacia Biotech media from the very beginning. Call us at 1 (800) 526 3593 from the USA, +81 (0)3 3492 6949 from Japan or +46 (0)18 16 50 11 from Europe and the rest of the world (or meet us on the Internet at <http://www.biotech.pharmacia.se>). Ask about the kit that saves an hour.

"Purity, simplicity and time savings: a product that gives you all these, lets you take a break from the lab for a bagel, coffee and...hmm, maybe a haircut!" Kyungsun Suh, Ph.D., at the Rockefeller University, New York, NY

**Pharmacia
Biotech**
Uppsala, Sweden. (And the rest of the world)

